BC-1215   Click here for help

GtoPdb Ligand ID: 12671

Synonyms: BC 1215 | BC1215
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: BC-1215 has been reported as an inhibitor of cytokine release that acts by targeting the ApaG motif in the C-terminal domain of ubiquitin E3 ligase F box component (Fbxo3) [2-4]. It blocks Fbxo3 interaction with the TRAF inhibitory protein Fbxl2, which results in elevation of Fbxl2-mediated degradation of TRAF proteins and ultimately decreases release of pro-inflammatory cytokines from monocytes. BC-1215 maps to compound 005 in patent US20180071232A, in which it is claimed for potential to treat inflammatory respiratory disease or injury [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 48.78
Molecular weight 394.51
XLogP 0.59
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES C1=CC(=NC=C1)C2=CC=C(C=C2)CNCCNCC3=CC=C(C=C3)C4=NC=CC=C4
Isomeric SMILES C1=CC=NC(=C1)C2=CC=C(C=C2)CNCCNCC3=CC=C(C=C3)C4=CC=CC=N4
InChI InChI=1S/C26H26N4/c1-3-15-29-25(5-1)23-11-7-21(8-12-23)19-27-17-18-28-20-22-9-13-24(14-10-22)26-6-2-4-16-30-26/h1-16,27-28H,17-20H2
InChI Key IXEPQJQQSLMESJ-UHFFFAOYSA-N
References
1. Chen B, Mallampalli R. (2018)
Compositions and methods for treating respiratory injury or disease.
Patent number: US20180071232A. Assignee: University of Pittsburgh , US Department of Veterans Affairs VA. Priority date: 17/11/2017. Publication date: 15/03/2018.
2. Hung KY, Liao WI, Pao HP, Wu SY, Huang KL, Chu SJ. (2019)
Targeting F-Box Protein Fbxo3 Attenuates Lung Injury Induced by Ischemia-Reperfusion in Rats.
Front Pharmacol, 10: 583. [PMID:31178737]
3. Jeon S, Kang J, Lee SB. (2023)
BC-1215 inhibits ATP-induced IL-1β secretion via the FBXL2-mediated ubiquitination and degradation of not only NLRP3, but also pro-IL-1β in LPS-primed THP-1 cells.
Biochem Biophys Res Commun, 657: 128-135. [PMID:37004285]
4. Mallampalli RK, Coon TA, Glasser JR, Wang C, Dunn SR, Weathington NM, Zhao J, Zou C, Zhao Y, Chen BB. (2013)
Targeting F box protein Fbxo3 to control cytokine-driven inflammation.
J Immunol, 191 (10): 5247-55. [PMID:24123678]